Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
22 Nov 2019
Historique:
entrez: 22 11 2019
pubmed: 22 11 2019
medline: 23 11 2019
Statut: epublish

Résumé

CDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders are investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). As of November 13, 2019, 49 states, the District of Columbia, and two U.S. territories (Puerto Rico and U.S. Virgin Islands) have reported 2,172 EVALI cases to CDC, including 42 (1.9%) EVALI-associated deaths. To inform EVALI surveillance, including during the 2019-20 influenza season, case report information supplied by states for hospitalized and nonhospitalized patients with EVALI were analyzed using data collected as of November 5, 2019. Among 2,016 EVALI patients with available data on hospitalization status, 1,906 (95%) were hospitalized, and 110 (5%) were not hospitalized. Demographic characteristics of hospitalized and nonhospitalized patients were similar; most were male (68% of hospitalized versus 65% of nonhospitalized patients), and most were aged <35 years (78% of hospitalized versus 74% of nonhospitalized patients). These patients also reported similar use of tetrahydrocannabinol (THC)-containing products (83% of hospitalized versus 84% of nonhospitalized patients). Given the similarity between hospitalized and nonhospitalized EVALI patients, the potential for large numbers of respiratory infections during the emerging 2019-20 influenza season, and the potential difficulty in distinguishing EVALI from respiratory infections, CDC will no longer collect national data on nonhospitalized EVALI patients. Further collection of data on nonhospitalized patients will be at the discretion of individual state, local, and territorial health departments. Candidates for outpatient management of EVALI should have normal oxygen saturation (≥95% while breathing room air), no respiratory distress, no comorbidities that might compromise pulmonary reserve, reliable access to care, strong social support systems, and should be able to ensure follow-up within 24-48 hours of initial evaluation and to seek medical care promptly if respiratory symptoms worsen. Health care providers should emphasize the importance of annual influenza vaccination for all persons aged ≥6 months, including persons who use e-cigarette, or vaping, products (2,3).

Identifiants

pubmed: 31751326
doi: 10.15585/mmwr.mm6846e1
pmc: PMC6871898
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1076-1080

Investigateurs

Kayla Anderson (K)
Francis B Annor (FB)
Sharyn E Brown (SE)
Angela D Coulliette-Salmond (AD)
Kristen N Cowan (KN)
Angela Dunn (A)
Aaron Fleishauer (A)
Jennifer Freed (J)
Macarena C Garcia (MC)
Janet Hamilton (J)
Donald Hayes (D)
Michelle M Hughes (MM)
Mia Israel (M)
Anne Kimball (A)
Hannah Kisselburgh (H)
Jennifer Layden (J)
Akaki Lekiachvili (A)
Matthew Lozier (M)
Ruth Lynfield (R)
Jonathan Meiman (J)
Erin D Moritz (ED)
Rashid Njai (R)
Jeffrey Ratto (J)
Sarah L Shafer (SL)
Stephen Soroka (S)
Natalie Sterrett (N)
Kimberly R Thomas (KR)
Bailey Wallace (B)
Angela K Werner (AK)
Jason Wilken (J)
Lauren B Zapata (LB)
Susan Hocevar Adkins (SH)
Emily A Kiernan (EA)
Ram Koppaka (R)
Emily H Koumans (EH)
Mark Layer (M)
Jaswinder Legha (J)
Michelle Montandon (M)
Sarah Reagan-Steiner (S)
David A Siegel (DA)
David N Weissman (DN)
Jennifer L Wiltz (JL)

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

MMWR Morb Mortal Wkly Rep. 2019 Oct 18;68(41):919-927
pubmed: 31633675
MMWR Morb Mortal Wkly Rep. 2019 Nov 01;68(43):985-989
pubmed: 31671085
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1040-1041
pubmed: 31725707
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1081-1086
pubmed: 31751322

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH